Rx Pimecrolimus 1%
Pimecrolimus is a calcineurin inhibitor. It suppresses T-cell activation by binding to the intracellular protein FKBP-12 and complexes with calcineurin dependent proteins resulting in decreased calcineurin phosphatase activity and reduced downstream activation of T lymphocytes.
Indications: Second line topical treatment of moderate to severe OLP, MMP, PV.
Contraindications: Hypersensitivity to the drug or any component of the formulation. Fungal, viral or bacterial infections of the oral cavity or throat.
Warnings/Precautions: Avoid use on malignant or premalignant skin conditions. Limit sun and ultraviolet light exposure; use appropriate sun protection. Do not use on areas of active bacterial or viral infection. Avoid in patients with atopic dermatitis. Do not use in immunocompromised patients.
Drug interactions: No significant drug interactions reported. Fungal, viral or bacterial infections of the oral cavity or throat.
Dosage form – 1% cream.
Topical – Apply thin coating of cream to lesion 2 to 4 times per day. Do not eat or drink for 30 minutes.
Monitor efficacy: Improved oral comfort, lesion resolution.
Monitor toxicity: Mucosal thinning, burning, candida superinfection.
Length of treatment: As may be required to manage painful exacerbations of OLP.
Cessation of treatment: Topical regimens may be discontinued without tapering.
Instructions to the patient: Use only as instructed. Do not swallow.
For additional information see DailyMed
Your session is about to expire. Do you want to continue logged in?
WARNING! You did not finish creating your certificate. Please click CONTINUE below to return to your previous page to complete the process. Failure to complete ALL the steps will result in a loss of this test score, and you will not receive credit for this course.